LifeVantage (NASDAQ:LFVN) Now Covered by Craig Hallum

Equities research analysts at Craig Hallum started coverage on shares of LifeVantage (NASDAQ:LFVN) in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $35.00 price target on the stock. Craig Hallum’s price objective suggests a potential upside of 42.86% from the stock’s current price.

Separately, Lake Street Capital started coverage on LifeVantage in a research note on Thursday, December 19th. They issued a “buy” rating and a $26.00 price target on the stock.

LifeVantage Stock Performance

Shares of LifeVantage stock opened at $24.50 on Tuesday. LifeVantage has a 52-week low of $5.22 and a 52-week high of $27.38. The company has a fifty day moving average of $16.28 and a 200-day moving average of $11.85. The stock has a market capitalization of $306.86 million, a price-to-earnings ratio of 76.56 and a beta of 0.82.

LifeVantage (NASDAQ:LFVN) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.15 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.15. The business had revenue of $47.21 million during the quarter. LifeVantage had a net margin of 2.11% and a return on equity of 29.24%.

Hedge Funds Weigh In On LifeVantage

Several hedge funds and other institutional investors have recently modified their holdings of LFVN. Ritholtz Wealth Management grew its stake in shares of LifeVantage by 62.0% in the third quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock worth $346,000 after purchasing an additional 10,974 shares during the last quarter. Barclays PLC grew its position in shares of LifeVantage by 38.2% in the 3rd quarter. Barclays PLC now owns 41,966 shares of the company’s stock worth $507,000 after buying an additional 11,608 shares during the last quarter. HighTower Advisors LLC purchased a new position in shares of LifeVantage during the third quarter valued at approximately $638,000. Capital Management Corp VA bought a new position in shares of LifeVantage during the third quarter valued at approximately $5,073,000. Finally, Renaissance Technologies LLC lifted its stake in LifeVantage by 2.1% in the second quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock worth $5,490,000 after acquiring an additional 17,300 shares during the period. 35.32% of the stock is owned by institutional investors.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.